Skip to main content

Bremelanotide Administration

Meaning

Bremelanotide Administration refers to the clinical use of the synthetic peptide bremelanotide, a melanocortin receptor agonist, for the pharmacological treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The compound is typically administered via a subcutaneous injection as needed, approximately 45 minutes prior to anticipated sexual activity. This targeted pharmacological approach aims to modulate specific central nervous system pathways involved in sexual arousal and desire.